bictegravir/emtricitabine/tenofovir alafenamide → μπικτεγκραβίρη / εμτρισιταβίνη / τενοφοβίρη αλαφεναμίδη
Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. It was approved for use in the United States in February 2018, and for use in the European Union in June 2018.
Bictegravir/emtricitabine/tenofovir alafenamide - Wikipedia